Earnings digests and industry comparisons for Japan's biggest listed companies.
237 reports(page 15 of 20)
Takeda reported that the US Food and Drug Administration has accepted its new drug application for the psoriasis treatment zasocitinib. The approval target date is set for the first quarter of 2027 following the priority review status.
Leopalace21 has resolved to cut dividends to zero for the fiscal year ending March 2027, aligning with support from tender offeror K891. This decision paves the way for a delisting and effectively pauses shareholder returns during the transition.
Leopalace21 has approved a tender offer from a consortium led by Kocom at JPY1,000 per share. The bid represents a 52 percent premium and clarifies the path toward delisting.
Chubu Electric has received an investigation report confirming flaws in the seismic motion evaluation method for the Hamama nuclear power plant. The disclosure highlights significant internal control defects, leaving the path to restart unclear and business impacts undetermined.
Sanwa announced the completion of its treasury stock acquisition program on October 1, having purchased an additional 320,000 shares in September. The consumer retail group effectively utilized its entire 10 billion yen budget, marking a robust commitment to shareholder returns.
Tokyo Century has decided to issue ¥20 billion in subordinated hybrid bonds to reinforce its financial foundation. The annual interest rate will be capped at 3.245 percent, aiming to strengthen the core surplus capital ratio.
Kakaku.com bidder Kamgras1 raised its TOB price to 3,680 yen per share. The move aims to rival Bain Capital's proposal and may lead to a merger or renewed competition for the privatization deal.
Machine tool giant Tsugami announced the early termination of its share buyback program as of September 10, 2026. The company purchased shares representing 92.00 percent of the approved limit.
NOF confirmed the completion of its share buyback program on September 10, utilizing almost the entire 5 billion yen limit. The company acquired approximately 0.89% of outstanding shares through this execution.
JACCS is reorganizing its credit approval operations into a seven-center system and implementing workforce rationalization measures in collaboration with the MUFG Group to drive cost efficiency and corporate value growth.
Sony Financial disclosed that its consolidated subsidiary, Sony Life Insurance, suffered cumulative losses exceeding 41 million yen from monetary fraud by sales staff. To prevent recurrence, the company is abolishing its exclusive agency system to strengthen direct headquarters oversight.
Chiba Bank acquired approximately 6.7 billion yen worth of treasury stock via market purchases during the August fiscal period. This move represents about 45 percent of its total purchase limit, signaling a push for capital efficiency and shareholder returns.
